Finance

Lists
Why is SVA up 4,76%?
Dive Deeper
SVA:TSE
Sernova Biotherapeutics Inc
CAD 0,11
+4,76%
(+0,0050) 1D
1 Okt., 15:53:11 GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for SVA...
Open
CAD 0,11
High
CAD 0,12
Low
CAD 0,11
Mkt. cap
39,76 m
Avg. vol.
336,75 k
Volume
37,34 k
52-wk high
CAD 0,20
52-wk low
CAD 0,08
EPS
-CAD 0,03
Beta
33,30
Shares outstanding
377,64 m
No. of employees
8
Open
CAD 0,11
High
CAD 0,12
Low
CAD 0,11
Mkt. cap
39,76 m
Avg. vol.
336,75 k
Volume
37,34 k
52-wk high
CAD 0,20
52-wk low
CAD 0,08
EPS
-CAD 0,03
Beta
33,30
Shares outstanding
377,64 m
No. of employees
8
News stories
From web sources and news partners
About Sernova Biotherapeutics Inc
CEOJonathan Rigby
Employees8
Founded2006
HeadquartersLondon, Ontario, Kanada
Sector-
Websitesernova.com
Last report
10 Sep. 2026
Fiscal period
Q3 2026
EPS / Est. (CAD)
-CAD 0,01 / -CAD 0,00
-100,00%miss
Revenue / Est. (CAD)
- / 0,00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in CAD
Okt. 2025
Jan. 2026
Apr. 2026
Jul. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
809,63 k
434,15 k
444,87 k
432,62 k
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,59 m
1,68 m
1,85 m
1,69 m
Operating expense
2,40 m
2,12 m
2,30 m
2,12 m
Total operating expenses
2,40 m
2,12 m
2,30 m
2,12 m
Operating income
-2,40 m
-2,12 m
-2,30 m
-2,12 m
Other non operating income
-
-
-
-
EBT including unusual items
-2,25 m
-2,41 m
-3,23 m
-2,57 m
EBT excluding unusual items
-2,26 m
-2,41 m
-3,23 m
-2,57 m
Income tax expense
-54,97 k
-72,00 k
-
-45,00 k
Effective tax rate
2,44%
2,99%
-
1,75%
Other operating expenses
-
-
-
-
Net income
-2,20 m
-2,33 m
-3,23 m
-2,53 m
Net profit margin
-
-
-
-
Earnings per share
-0,01
-0,01
-0,01
-0,01
Interest and investment income
260,60 k
-
413,00
-
Interest expense
-
-477,12 k
-920,95 k
-260,18 k
Net interest expenses
260,60 k
-477,12 k
-920,53 k
-260,18 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,34 m
-2,11 m
-2,29 m
-2,11 m
Gain or loss from assets sale
-4,25 k
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme